Table 1. Baseline characteristics of study population stratified by RVFWLS above and below the median (−16%).

BMI=Body Mass Index, LGE=Late Gadolinium Enhancement, LVEDV=Left Ventricular End Diastolic Volume, LVEF=Left Ventricular Ejection Fraction, LVESV=Left Ventricular End Systolic Volume, RA=Right Atrial, RVEDV = Right Ventricular End Diastolic Volume, RVEF=Right Ventricular Ejection Fraction, RVESV = Right Ventricular End Systolic Volume, SD=standard deviation. TAPSE=Tricuspid Annular Plane Systolic Excursion.

CHARACTERISTICS	Total	RVFWLS <median (−16%)	RVFWLS ≥median (−16%)	P Value
Age (±SD), years	60.60 (±18.6)	59.14 (±19.7)	61.87 (±17.2)	0.123
Male %	41.0	37.9	44.3	0.126
BMI (±SD), kg/m2	27.3 (±5.9)	27.4 (±6.0)	27.1 (±5.7)	0.592
Diabetes %	16.5	15.7	17.4	0.592
Hyperlipidemia %	35 6	32.6	39.0	0.161
Hypertension %	53.7	49.4	58.7	0.048
Smoking %	27.3	26.9	27.8	0.830
Aspirin %	42.4	39.5	45.7	0.191
Statin %	29.8	27.6	32.3	0.284
ACE inhibitor %	25.7	22.9	28.9	0.158
Beta Blocker %	36.0	32.3	40.4	0.083
Pulmonary hypertension %	14.3	12.5	16.3	0.208
Left sided valve disease*%	42.1	36.4	48.1	0.006
Heart Rate (±SD), beats/min	79.8 (±18.2)	77.5 (±15.8)	82.4 (±20.2)	0.004
Systolic BP (±SD), mm Hg	122(±22)	125(±23)	120(±21)	0.024
Diastolic BP (±SD), mm Hg	72(±14)	72(±14)	72(±14)	0.950
LVEDV (±SD), ml	136(±65)	126(±51)	145(±75)	<0.001
LVESV (±SD), ml	69(±60)	5 5 (±41)	83(±72)	<0.001
LVEF (±SD), %	52.4 (±15.5)	57.0 (±12.0)	47.4 (±17.2)	<0.001
LGE %	36.6	25.4	48.5	<0.001
TAPSE (±SD), mm	14 (±7)	16 (±7)	11 (±6)	<0.001
Tricuspid Valve Annulus (±SD), mm	41(±8)	40(±8)	42(±8)	0.017
RA area, cm2	37(±14)	36(±14)	37(±14)	0.284
RVEDV (±SD), ml	213(±99)	200(±96)	228(±101)	0.001
RVESV (±SD), ml	137(±80)	115(±65)	159(±88)	<0.001
RVEF (±SD), %	37.2 (±14.2)	42.1 (±13.2)	32.0 (±13.5)	<0.001

^*moderate or more left sided valve disease.